Intrahepatic Cholestasis of Pregnancy

Stanisław M. Jurk; Andreas E. Kremer; Ekkehard Schleussner

doi:10.1055/a-1522-5178

Geburtshilfe und Frauenheilkunde, Table of Contents

CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(08): 940-947
DOI: 10.1055/a-1522-5178

GebFra Science

Review/Übersicht

Intrahepatische Schwangerschaftscholestase

Article in several languages: English | deutsch

Stanisław M. Jurk

¹Leipzig, Germany

,

Andreas E. Kremer

²Medizinische Klinik 1, Universitätsklinikum Erlangen, Erlangen, Germany

³Klinik für Gastroenterologie und Hepatologie, Universitätsspital Zürich, Zürich, Switzerland

,

Ekkehard Schleussner

⁴Klinik für Geburtsmedizin, Universitätsklinikum Jena, Jena, Germany

› Author Affiliations

Abstract

Zusammenfassung

Die intrahepatische Schwangerschaftscholestase (ICP) ist eine seltene, aber potenziell schwerwiegende Schwangerschaftskomplikation, deren Leitsymptom ein die schwangere Frau quälender Pruritus bei erhöhten Serumspiegeln der Gallensäuren ist. Erhöhte Serumkonzentration gilt als Prädiktor für ein schlechtes perinatales Outcome bis hin zum intrauterinen Tod. Als Therapie der Wahl hat sich Ursodesoxycholsäure (UDCA) zur signifikanten Symptomverbesserung und Verminderung der Cholestase in der klinischen Versorgung etabliert. Die engmaschige Überwachung und Behandlung von Schwangeren mit einer schweren intrahepatischen Cholestase sollte immer in einem Perinatalzentrum interdisziplinär durch Perinatologen und Hepatologen erfolgen, damit neben den maternalen Beschwerden die wesentlich erhöhte perinatale Morbidität und Mortalität minimiert werden.

Schlüsselwörter

Schwangerschaftscholestase - Pruritus - Gallensäuren - Schwangerschaftsvorsorge - Geburtseinleitung - Fruchttod

Full Text

References

References/Literatur
1 Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis 2007; 2: 26
2 Floreani A, Gervasi MT. New insights on intrahepatic cholestasis of pregnancy. Clin Liver Dis 2016; 20: 177-189
3 Ovadia C, Williamson C. Intrahepatic cholestasis of pregnancy: recent advances. Clin Dermatol 2016; 34: 327-334
4 Geenes V, Williamson C, Chappel LC. Intrahepatic cholestasis of pregnancy. Obstet Gynaecol 2016; 18: 273-281
5 Smith DD, Rood KM. Intrahepatic Cholestasis of Pregnancy. Clin Obstet Gynecol 2020; 63: 134-151
6 Ahlfeld F. Berichte und Arbeiten aus der geburtshilflich-gynaekologischen Klinik zu Giessen 1881 – 1882. Leipzig: Grunow FW; 1883: 148
7 Dixon PH, Wadsworth CA, Chambers J. et al. A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. Am J Gastroenterol 2014; 109: 76-84
8 Jacquemin E, De Vree JM, Cresteil D. et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120: 1448-1458
9 Lammert F, Marschall HU, Glantz A. et al. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol 2000; 33: 1012-1021
10 Reyes H, Sjövall J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann Med 2000; 32: 94-106
11 Gonzalez MC, Reyes H, Arrese M. et al. Intrahepatic cholestasis of pregnancy in twin pregnancies. J Hepatol 1989; 9: 84-90
12 Raz Y, Lavie A, Vered Y. et al. Severe intrahepatic cholestasis of pregnancy is a risk faktor for preeclampsia in singleton and twin pregnancies. Am J Obstet Gynecol 2015; 213: 395.e1-395.e8
13 Kremer AE, Wolf K, Ständer S. Intrahepatische Schwangerschaftscholestase. Hautarzt 2017; 68: 95-102
14 Kauppila A, Korpela H, Mäkilä UM. et al. Low serum selenium concentration and glutathione peroxidase activity in intrahepatic cholestasis of pregnancy. Br Med J (Clin Res Ed) 1987; 294: 150-152
15 Wikström Shemer E, Marschall HU. Decreased 1,25-dihydroxy vitamin D levels in women with intrahepatic cholestasis of pregnancy. Acta Obstet Gynecol Scand 2010; 89: 1420-1423
16 Gençosmanoğlu Türkmen G, Vural Yilmaz Z, Dağlar K. et al. Low serum vitamin D level is associated with intrahepatic cholestasis of pregnancy. J Obstet Gynaecol Res 2018; 44: 1712-1718
17 Marshall HU, Wikstrom Shermer E, Ludvigsson JF. Intrahepatic cholestasis of pregnancy ans associated hepatobiliary disease: a population-base cohort study. Hepatology 2013; 58: 1385-1391
18 Wijarnpreecha K, Thongprayoon C, Sanguankeo A. et al. Hepatitis C infection and intrahepatic cholestasis of pregnancy: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017; 41: 39-45
19 Bolubkas FF, Bolubkas C, Balaban HY. et al. Intrahepatic Cholestasis of Pregnancy: Spontaneous vs. in vitro Fertilization. Euroasian J Hepat-Gastroenterol 2017; 7: 126-129
20 Abu-Hayyeh S, Ovadia C, Lieu T. et al. Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of preganancy and pruritus gravidarum. Hepatology 2016; 63: 1287-1298
21 Tsur A, Kan P. et al. Datoc i et al. 68: Vaginal progesterone treatment is associated with intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol 2020; 222: S58-S59
22 Glantz A, Marshall HU, Mattsson LA. Intraheptaic cholestasis of pregnancy: relationship between bile acid levels and fetal complication rates. Hepatology 2004; 40: 467-474
23 WHO. Medical Eligibility Criteria for Contraceptive Use. 5th ed. World Health Organization; 2015
24 Kondrackiene J, Kupcinskas L. Intrahepatic cholestasis of pregnancy – current achievements and unsolved problems. World J Gastroenterol 2008; 14: 5781-5788
25 Geenes V, Lövgren-Sandblom A, Benthin L. et al. The Reversed Feto-Maternal Bile Acid Gradient in Intrahepatic Cholestasis of Pregnancy IS Corrected by Ursodeoxycholic Acid. PLoS One 2014; 9: e83828
26 Brites D. Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid therapy in cholestasis of pregnancy. Ann Hepatol 2002; 1: 20-28
27 Keitel V, Dröge C, Häussinger D. Genetische Ursachen cholestatischer Lebererkrankungen. Falk Gastro-Kolleg 3/2019. Accessed March 30, 2020 at: https://www.drfalkpharma.de/uploads/tx_toccme2/FGK_3_19_Keitel_Web.pdf
28 Dixon PH, Williamson C. The pathophysiology on intrahepatic cholestasis pf pregnancy. Clin Res Hepatol Gastroenterol 2016; 40: 141-153
29 Dixon PH, van Mil SW, Chambers J. et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 2009; 58: 537-544
30 Dixon PH, Sambrotta M, Chambers J. et al. An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Sci Rep 2017; 7: 11823
31 Henkel SA, Squires JH, Ayers M. et al. Expanding etiology of progressive familial intrahepatic cholestasis. World J Hepatol 2019; 11: 450-463
32 Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol 2014; 124: 120-133
33 Geenes V, Chappell LC, Seed PT. et al. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology 2014; 59: 1482-1491
34 Brouwers L, Koster MP, Page-Christiaens GC. et al. Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. Am J Obstet Gynecol 2015; 212: 100.e1-100.e7
35 Arthuis C, Diguisto C, Lorphelin H. et al. Perinatal outcomes of intrahepatic cholestasis during pregnancy: An 8-year case-control study. PLoS One 2020; 15: e0228213
36 Ovadia C, Seed PT, Sklavounos A. et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet 2019; 393: 899-909
37 Al Inizi S, Gupta R, Gale A. Fetal tachyarrhythmia with atrial flutter in obstetric cholestasis. Int J Gynecol Obstet 2006; 93: 53-54
38 Ataalla WM, Ziada DH, Gaber R. et al. The impact of total bile acid levels on fetal cardiac function in intrahepatic cholestasis of pregnancy using fetal echocardiography: a tissue Doppler imaging study. J Matern Fetal Neonatal Med 2016; 29: 1445-1450
39 Sanhal CY, Kara O, Yucel A. Can fetal left ventricular modified myocardial performance index predict adverse perinatal outcomes in intrahepatic cholestasis of pregnancy?. J Matern Fetal Neonatal Med 2017; 30: 911-916
40 Williamson C, Miragoli M, Sheikh Abdul Kadir S. et al. Bile acid signaling in fetal tissues: implications for intrahepatic cholestasis of pregnancy. Dig Dis 2011; 29: 58-61
41 Germain AM, Kato S, Carvajal JA. et al. Bile acids increase response and expression of human myometrial oxytocin receptor. Am J Obstet Gynecol 2003; 189: 577-582
42 Zhao P, Zhang K, Yao Q. et al. Uterine contractility in intrahepatic cholestasis of pregnancy. J Obstet Gynaecol 2014; 34: 221-224
43 Chappell LC, Bell JL, Smith A. et al. for the PITCHES study group. Ursodeoxycholic acid versus placebo in women with intraheptic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet 2019; 394: 849-860
44 Kawakita T, Parikh LI, Ramsey PS. et al. Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol 2015; 213: 570.e1-570.e8
45 Di Mascio D, Quist-Nelson J, Riegel M. et al. Perinatal death by bile acid levels in intrahepatic cholestasis of pregnancy: a systematic review. J Matern Fetal Neonatal Med 2019;
46 Altshuler G, Arizawa M, Molnar-Nadasdy G. Meconium-induced Umbilical Cord Vascular Necrosis and Ulceration: A Potential Link Between the Placenta and Poor Pregnancy Outcome. Obstet Gynecol 1992; 79 (5 Pt 1): 760-766
47 Lammert F, Rath W, Matern S. Lebererkrankungen in der Schwangerschaft. Molekulare Pathogenese und interdisziplinäres Management. Gynäkologe 2004; 37: 418-426
48 Lammert F, Rath W. Lebererkrankungen. In: Kainer F. Hrsg. Facharztwissen Geburtsmedizin. 3. Aufl.. München: Elsevier GmbH; 2016: 450-453
49 Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus. Gastroenterology 1977; 73: 1125-1130
50 Kremer AE, Bolier R, Dixon PH. et al. Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. J Hepatol 2015; 62: 897-904
51 Wikström Shemer EA, Stephansson O, Thuresson M. et al. Intrahepatic cholestasis of pregnancy and cancer, immunemediated and cardiovascular diseases: A population-based cohort study. J Hepatol 2015; 63: 456-461
52 Mor M, Shmueli A, Krispin E. et al. Intrahepatic cholestasis of pregnancy as a risk factor for preeclampsia. Arch Gynecol Obstet 2020; 301: 655-664
53 Martineau MG, Raker C, Dixon PH. et al. The metabolic profile of intrahepatic cholestasis of pregnancy is associated with impaired glucose tolerance, dysllipidemia, and increased fetal growth. Diabetes Care 2015; 38: 243-248
54 Majewska A, Godek B, Bomba-Opon D. et al. Association between intrahepatic cholestasis in pregnancy and gestational diabetes mellitus. A retrospective analysis. Ginekol Pol 2019; 90: 458-463
55 Ropponen A, Sund R, Riikonen S. et al. Intrahepatic cholestasis of pregnancy an an indicator of liver and biliary diseases: a population-based study. Hepatology 2006; 43: 723-728
56 Sinakos E, Marshall HU, Kowdley KV. et al. Bile acid chnages after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology 2010; 52: 197-203
57 Hammoud GM, Ibdah JA. The Liver in Pregnancy. In: Boyer TD, Manns MP, Sanyal AS. eds. Zakim and Boyerʼs Hepatology. A Textbook of Liver Disease. 6th ed. Philadelphia: Saunders; 2012: 919-940
58 Parquet M, Metman EH, Raizman A. et al. Bioavailability, gastrointestinal transit, solubilization and faecal excretion of orsodeoxycholic acid in man. Eur J Clin Invest 1985; 15: 171-178
59 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267
60 Accessed June 17, 2021 at: https://www.icpsupport.org/protocol.shtml
61 Bacq Y, Sentilhes L, Reyes HB. et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 2012; 143: 1492-1501
62 Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009; 15: 2049-2066
63 Manna LB, Ovadia C, Lövgren-Sandblom A. et al. Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study. BJOG 2019; 126: 1633-1640
64 Gurung V, Middleton P, Milan SJ. et al. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst Rev 2013; (06) CD000493
65 GrandʼMaison S, Durand M, Mahone M. The effects of ursodeoxycholic acid treatment for intrahepatic cholestasis of pregnancy on maternal and fetal outcomes: a meta-analysis including non-randomized studies. J Obstet Gynaecol Can 2014; 36: 632-641
66 Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005; 129: 894-901
67 Roncaglia N, Locatelli A, Arreghini A. et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG 2004; 111: 17-21
68 Zhang Y, Lu L, Victor DW. et al. Ursodeoxycholic Acid and S-adenosylmethionine for the Treatment of Intrahepatic Cholestasis of Pregnancy: A Meta-analysis. Hepat Mon 2016; 16: e38558
69 Triunfo S, Tomaselli M, Ferraro MI. et al. Does mild intrahepatic cholestasis of pregnancy require an aggressive management? Evidence from a prospective observational study focused on adverse perinatal outcomes and pathological placental findings. J Matern Fetal Neonatal Med 2020;
70 Geenes V, Chambers J, Khurana R. et al. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. Eur J Obstet Gynecol Reprod Biol 2015; 189: 59-63
71 Walker KF, Chappell LC, Hague WM. et al. Pharmacological interventions for treating intrahepatic cholestasis of pregnancy. Cochrane Database Syst Rev 2020; (07) CD000493
72 Bicocca MJ, Sperling JD, Chauhan SP. Intrahepatic cholestasis of pregnancy: Review of six national and regional guidelines. Eur J Obstet Gynecol Reprod Biol 2018; 231: 180-187
73 Kehl S, Abou-Dakn M. et al. für die DGGG und Arbeitsgemeinschaft für Geburtshilfe und Pränatalmedizin in der DGGG e. V.. S2k-Leitlinie Geburtseinleitung. Accessed December 27, 2020 at: https://www.awmf.org/uploads/tx_szleitlinien/015-088l_S2k_Geburtseinleitung_2020-12.pdf
74 Royal College of Obstetricians and Gynaecologists. Obstetric Cholestasis. RCOG Green-top Guideline No. 43. London: RCOG; 2011
75 Bile Acid Effects in Fetal Arrhythmia Study (BEATS). Accessed August 31, 2020 at: https://clinicaltrials.gov/ct2/show/NCT03519399
76 Lo JO, Shaffer BL, Allen AJ. et al. Intrahepatic Cholestasis of Pregnancy and Timing of Delivery. J Matern Fetal Neonatal Med 2015; 28: 2254-2258
77 Puljic A, Kim A, Page J. et al. The risk of infant and fetal death by each additional week of expectant management in intrahepatic cholestasis of pregnancy by gestational age. Am J Obstet Gynecol 2015; 212: 667.e1-e667.e5
78 Mitchell A, Ovadia C, Syngelaki A. et al. Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study. Br J Obstet Gynaecol 2021;
79 Ovadia C, Sajous J, Seed PT. et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2021; 6: 547-558 Online: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00074-1/fulltext